The selection of appropriate treatment options for schizophrenia patients requires careful consideration of various factors, including efficacy, tolerability, and safety. However, the lack of reliable biomarkers makes it challenging to precisely match the mechanism of action of the drug to the patient’s specific pathology. Despite this, clinicians often rely on trial and error to find the most effective medication for each individual. The development of novel agents targeting dopaminergic neurotransmission offers promising opportunities, but researchers emphasize the need for better patient stratification and long-term safety monitoring. Combining new drugs with traditional medications may enhance treatment outcomes, but further research is necessary to evaluate potential safety risks.